US Patent Office won’t review two Novo Nordisk patents for Wegovy, Ozempic
By Blake Brittain WASHINGTON (Reuters) – A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes…
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
By Ludwig Burger (Reuters) – Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit. In a statement on Wednesday, it…
Breaking News
